Cite
HARVARD Citation
Saiag, P. et al. (2021). Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. European journal of cancer. pp. 57-65. [Online].